Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Tax Provisions: 2022-2025

Historic Tax Provisions for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $166,000.

  • Centessa Pharmaceuticals' Tax Provisions fell 72.70% to $166,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 15.42%. This contributed to the annual value of $2.8 million for FY2024, which is 111.35% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Tax Provisions is $166,000, which was down 78.66% from $778,000 recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Tax Provisions high stood at $1.4 million for Q1 2025, and its period low was -$24.1 million during Q2 2023.
  • Over the past 3 years, Centessa Pharmaceuticals' median Tax Provisions value was $677,000 (recorded in 2023), while the average stood at -$1.8 million.
  • The largest annual percentage gain for Centessa Pharmaceuticals' Tax Provisions in the last 5 years was 746.25% (2023), contrasted with its biggest fall of 109,222.73% (2023).
  • Over the past 4 years, Centessa Pharmaceuticals' Tax Provisions (Quarterly) stood at -$664,000 in 2022, then spiked by 272.29% to $1.1 million in 2023, then dropped by 8.22% to $1.1 million in 2024, then plummeted by 72.70% to $166,000 in 2025.
  • Its Tax Provisions stands at $166,000 for Q3 2025, versus $778,000 for Q2 2025 and $1.4 million for Q1 2025.